ESR1 and breast carcinoma: In the present study we have investigated whether the second generation PI carfilzomib exerts inhibitory effects on ERα+ breast cancer cells equivalent to those of bortezomib, and whether both drugs can target endocrine therapy-resistant ERα+/HER2-amplified breast cancer cells.